Zurück zu den Rankings

Sotera Health Company (SHC)

Überbewertet
HealthcareDiagnostics & ResearchUnited States

Fundamental

58

Kurs

$18.26

Marktkapitalisierung

$5.28B

Teil 1 · Was das Unternehmen wert ist

Übersicht

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilanz & Liquidität

Umsatz

$1.22B

Letzte 12 Monate (bis 30.6.2026)

Nettogewinn

$163M

Letzte 12 Monate (bis 30.6.2026)

Freier Cashflow

$149M

Gesamtes Eigenkapital

$606M

Gesamtverbindlichkeiten

$2.66B

Current Ratio

2.80

Zinsdeckungsgrad

-

Schulden/EBITDA

3.93

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Allgemeiner FallÜberbewertet

Innerer Wert

$13.15

Aktueller Kurs

$18.26

Sicherheitsmarge

-38.9%

Innerer-Wert-Spanne

$8.55 - $17.76

Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.

Bewertungsmethoden

Kursziel der Analysten:$22.72
Diskontierter Cashflow (DCF):$6.62
Gewinnmultiplikator (P/E):$10.22
Graham-Wachstumsformel:$9.28
Ertragskraftwert (EPV):$7.14
Gerechtfertigtes P/B:$4.06
Dividendendiskontierung (Gordon):Nicht genügend Daten zur Berechnung
P/FFO, Funds from Operations:$9.69
Gewinn im Zyklusmittel:$21.63
Umsatzmultiplikator:$16.63
Analystenkonsens:Starker Kauf (12B / 3H / 0S)
Letzte Gewinnüberraschung:+7.62%

Bewertungskennzahlen

P/E-Verhältnis

32.44

ROE

12.9%

P/B-Verhältnis

7.93

P/FCF

46.82

Bruttomarge

55.0%

ROIC

-

Rentabilitäts-Radar

Wertschöpfung (Wettbewerbsvorteil)

ROIC

-

WACC

10.7%

ROIC − WACC

-

Fundamentalanalyse-Kriterien

Bestanden (13)

  • EPS shows upward trend
  • Gross Margin 55.0%
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 26.8%
  • Revenue Growth 5Y 7.3%
  • Analyst Consensus 80% Buy
  • Earnings Surprise avg 8.4%
  • Earnings Quality (OCF/NI) 1.79
  • Net Margin Trend 13.4% vs 2.1%
  • Piotroski F-Score 6/9

Nicht bestanden (9)

  • Price CAGR -6.54%
  • P/FCF 46.82
  • P/B Ratio 7.93
  • Debt/Equity ratio
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Share Dilution 4.0%

Nicht verfügbar (5)

  • ROIC NaN%
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Interest Coverage
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

6/9

Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit

score
criteria

Gewinnqualität

1.79

Hohe Qualität: Gewinne durch Cashflow gedeckt

Aktienverwässerung

4.0%

Neue Aktien werden ausgegeben, Eigentum wird verwässert

Institutionelle Beteiligungen

Unternehmensführung

Führungsteam

NamePositionAlter
Mr. Michael B. Petras Jr.Executive Chairman of the Board56
Mr. Jonathan M. LyonsSenior VP & CFO47
Mr. Michael P. RutzPresident of Sterigenics U.S., LLC54
Mr. Alton E. ShaderCEO & Director52
Mr. Robert G. HauzieChief Information Officer-
Ms. Erika OstrowskiSenior VP, General Counsel & Corporate Secretary-
Ms. Kristin A. GibbsChief Marketing Officer-
Mr. William O. Lehmann Jr., J.D., M.B.A.Senior Vice President of Strategy & Corporate Development59
Ms. Sally R. TurnerChief Human Resources Officer-
Ms. Danielle J. MentureSenior Vice President of Global Environmental, Health & Safety and Sustainability-

Prüfungsrisiko

4

Vorstandsrisiko

8

Vergütungsrisiko

5

Aktionärsrechterisiko

7

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Dokumente

  • Jahresbericht (10-K)

    Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.

    Eingereicht am 2026-02-24

    Dokument ansehen
  • Quartalsbericht (10-Q)

    Ein Update zur finanziellen Entwicklung der letzten drei Monate.

    Eingereicht am 2026-08-06

    Dokument ansehen
  • Ad-hoc-Meldung (8-K)

    Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.

    Eingereicht am 2026-08-14

    Dokument ansehen

via SEC EDGAR

Ertragshistorie

via SEC EDGAR

Latest News

Recent headlines for SHC, sourced from Markets Gazette.

  • 3/15/2026NEUTRAL
    Sotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals

    Sotera Health Company shares have seen an 18% increase over the past year, with recent activity indicating a significant stake trim by an insider amounting to $37 million. Sotera Health provides crucial sterilization and laboratory testing services to highly regulated industries globally, playing a vital role in maintaining essential supply chains. While the stock has performed well, the substantial insider sale could signal a divergence of opinion on future valuation or a need for liquidity, warranting investor attention.

  • 3/2/2026NEGATIVE
    Sotera Health Up 30% This Past Year, so Why Did One Fund Sell $4 Million in Shares?

    Sotera Health, a global provider of sterilization and laboratory solutions to the healthcare, pharmaceutical, and food industries, has seen an impressive 30% growth over the past year. Despite this robust performance, an unidentified fund divested $4 million worth of shares. This move raises questions among investors: why would an institutional entity sell such a significant stake in a rapidly growing company? It could signal strategic profit-taking, a portfolio rebalancing, or potentially a less optimistic view on the company's future prospects not yet apparent to the broader market. Investors should closely monitor upcoming developments and the rationale behind this significant divestment.

  • 2/24/2026NEUTRAL
    Insights into Sotera Health Q4 Earnings

    Investors are keenly awaiting insights into Sotera Health's fourth-quarter earnings, a pivotal event for assessing the company's performance and future outlook. Analyzing quarterly results is crucial for understanding financial health, revenue growth, and profitability, all of which directly influence market sentiment and investment decisions. While specific details are yet to be disclosed, market focus remains on how Sotera Health navigated operational challenges and opportunities during the period. Key data points, such as revenue, earnings per share (EPS), and future guidance, will be scrutinized to identify trends and potential catalysts for the stock price. Results meeting or exceeding expectations could bolster confidence, whereas a disappointment might trigger a negative reaction.

via Markets Gazette